— January 7, 2026

One CAR-T Infusion Pushed Refractory Lupus, Scleroderma, and Myositis Into Drug-Free Remission

On January 7, 2026, Nature Medicine published online the results of the CASTLE trial — a phase 1/2 “basket” study from Georg Schett’s rheumatology group at Friedrich-Alexander University in Erlangen, Germany. The headline is unusual for autoimmune medicine: a single infusion of engineered immune cells put most patients with three of the hardest-to-treat autoimmune diseases into remission and let every one of them stop all of their immune-suppressing drugs. The same borrowed-from-cancer technology, aimed at the same molecular target, worked across diseases that rheumatologists normally treat as separate problems.

What CAR-T therapy is, and why it was pointed at autoimmunity

CAR-T stands for chimeric antigen receptor T-cell therapy. A patient’s own T cells are drawn out, genetically re-programmed in a lab to recognize a specific surface tag, then grown up and infused back in as a living drug that hunts down every cell carrying that tag. Oncologists have used it since 2017 to clear blood cancers. The tag in this trial is CD19, a marker on B cells — the immune cells that manufacture antibodies. In lupus, systemic sclerosis, and inflammatory myositis, some of those B cells churn out autoantibodies that attack the body’s own tissues. The logic of CASTLE is a deep “immune reset”: wipe out the CD19-positive B cells entirely, and let the immune system regrow from scratch without the self-attacking clones.

The numbers and the design

CASTLE enrolled 24 patients whose disease had already failed standard therapy: 10 with systemic lupus erythematosus (SLE), 9 with systemic sclerosis (SSc), and 5 with idiopathic inflammatory myopathies (IIM). Each received one infusion of an autologous CD19-directed CAR-T product, then was followed over a 24-week primary observation window. The results, by the trial’s pre-defined endpoints:

• 9 of 10 lupus patients reached DORIS remission — the formal international “Definition Of Remission In SLE” — and their anti–double-stranded-DNA autoantibodies turned negative.
• All 9 systemic sclerosis patients showed no disease progression.
• 4 of 5 myositis patients reached an ACR major or moderate response.
• 22 of the 24 patients hit their pre-defined efficacy target, and every patient stayed off glucocorticoids and all other immunosuppressive drugs for the entire 24-week period.

On safety, the trial hit its primary endpoint: no cytokine release syndrome above grade 2, and no ICANS (the neurotoxicity syndrome that can accompany CAR-T). Cytokine release syndrome is the flu-like inflammatory surge that follows infusion; keeping it at grade 2 or below means it stayed manageable rather than life-threatening.

Why it matters

Two things make this more than another small case series. First, the basket design: instead of studying one disease, CASTLE deliberately tested the same intervention across three, and it worked in all three. That is real-world support for a unifying idea — that a shared driver (autoantibody-producing B cells) sits underneath conditions that look clinically different. Second, the endpoint is not merely “lower disease activity.” It is drug-free remission: patients came off the steroids and immunosuppressants that carry their own heavy long-term costs. For people with treatment-refractory rheumatic disease, who often cycle through drug after drug, the prospect of a one-time reset is genuinely different in kind.

The honest caveats

This is an early-phase result, and it should be read as a strong signal, not a settled treatment. The specifics matter:

• It is small and uncontrolled. Twenty-four patients, open-label, no placebo or comparison group. Impressive response rates in a tiny, single-program cohort routinely shrink when tested in larger, randomized trials.
• The follow-up is short. Twenty-four weeks tells us about induction of remission, not durability. The central open question in autoimmune CAR-T is whether the self-reactive B cells eventually return — and if they do, whether the disease comes back with them. Longer follow-up is needed.
• It is not a gentle procedure. CAR-T requires lymphodepleting chemotherapy beforehand, carries infection risk while B cells are depleted, and the broader CAR-T field carries a class-wide FDA warning about rare secondary malignancies. It is delivered at specialized centers, is expensive, and involves manufacturing cells individually for each patient.
• It is for refractory disease only. These were patients who had exhausted conventional options — not people with newly diagnosed or mild disease, for whom the risk-benefit math is entirely different.

The takeaway

CASTLE is one of the most encouraging autoimmune results in years: a single CD19 CAR-T infusion drove drug-free remission across lupus, scleroderma, and myositis, with a safety profile that stayed within manageable bounds. It strengthens the case that a B-cell “reset” can rewrite the course of several diseases at once. But it is a first-in-class, early-phase study — the field now needs larger controlled trials, longer follow-up to prove the remissions last, and clarity on which patients justify the procedure’s cost and risk. If those confirm, therapies that today target rheumatoid arthritis and lupus one drug at a time may be joined by an occasional, decisive immune reset. That future is not here yet — but on January 7, 2026, it moved measurably closer.

Sources

1. Müller F, Taubmann J, Völkl S, et al. (senior author Schett G). CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial. Nature Medicine. 2026 Mar;32(3):1142–1151. Epub 2026 Jan 7. doi:10.1038/s41591-025-04185-6 · PMID 41501497
2. Müller F, Boeltz S, Knödler J, et al. CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-up (background from the same Erlangen group). New England Journal of Medicine. 2024;390:687–700. doi:10.1056/NEJMoa2308917
3. PubMed topic search: CD19 CAR-T in autoimmune disease